Medicines A–Z
L
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Liraglutide (Saxenda®) (GLP1s should all be prescribed by brand name) | The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Saxenda®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. |
|
 |
Liraglutide (Victoza®) injection (GLP1s should all be prescribed by brand name) | THIS IS FOR DIABETES ONLY. Prescribe by brand (Victoza®) to avoid patients inadvertently receiving a different product licensed for obesity. 1.8 mg is non-formulary. |
|
 |
Lisdexamfetamine | ESCAs and additional advice in relation to age of patient and CCG |
|
|
Lisdexamfetamine | ESCAs and additional advice in relation to age of patient and CCG |
|
|
Lisinopril tablets | ||
|
Lithium carbonate M/R tablet (Priadel) | Specialist initation only, ESCA |
|
|
Lithium citrate liquid priadel | Specialist initiation only, ESCA |
|
|
Lixisenatide (Lyxumia®) | 1st line choice GLP1 for co-prescribing with insulin. RICaD. |
|
|
Lizinna | Umbrella service only |
|
|
Loestrin 20 | Umbrella servide only - puberty induction |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
